Transforming US drug access and production: MFN pricing deals and historic manufacturing investments
In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the pharmaceutical supply…
In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the pharmaceutical supply…
Mergers and acquisitions (M&As) in the pharmaceutical industry already witnessed a 31% increase in total deal value from $137.1 billion…
Arog Pharmaceuticals presented new results from a Phase III trial at the American Society of Hematology (ASH) Annual Meeting 2025,…
Bristol Myers Squibb’s golcadomide, a first-in-class, oral CELMoD (cereblon E3 ligase modulator), has shown compelling activity as monotherapy and in…
The bipolar disorder (BD) market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and…
The chronic kidney disease (CKD)-hyperparathyroidism (HPT), hyperphosphatemia (HP) and hyperkalemia (HK) market is poised to grow at a compound annual…
The use of real-world evidence (RWE) began gaining traction decades ago, primarily as a response to the limitation around traditional…
Antibody drug conjugates (ADCs) have gained significant momentum in recent years, due to their clinical successes in cancer treatment. Since…
When US Food and Drug Administration (FDA) inspectors arrived unannounced at Hetero Labs' warehouse facility in Visakhapatnam, India, on 19…
The pharmaceutical services industry is undergoing both innovation and consolidation – trends that are redefining competition and opening new strategic…